3.85  -0.34 (-8.11%)		07-31 16:00
Open: 4.05 High: 4.66 Volume: 7,239,812		Pre. Close: 4.19 Low: 3.8 Market Cap: 223(M)

Short term
Mid term
Targets	6-month :	23.64	1-year :	36.12
Resists	First :	20.24	Second :	30.93
Pivot price	16.06
Supports	First :	2.96	Second :	2.46
MAs	MA(5) :	8.26	MA(20) :	17.68
	MA(100) :	27.76	MA(250) :	20.03
MACD	MACD :	-4.9	Signal :	-3.3
%K %D	K(14,3) :	5.3	D(3) :	7.9
RSI	RSI(14): 11.4
52-week	High :	40.36	Low :	2.96

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ CAPR ] has closed above bottom band by 3.0%. Bollinger Bands are 236.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

If tomorrow:	Open lower	Open higher
High:	4.69 - 4.74	4.74 - 4.76
Low:	3.72 - 3.77	3.77 - 3.8
Close:	3.79 - 3.87	3.87 - 3.92

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Sat, 01 Aug 2026
symbol__ Stock Quote Price and Forecast - CNN

Sat, 01 Aug 2026
Wall Street Zen Downgrades Capricor Therapeutics (NASDAQ:CAPR) to Strong Sell - MarketBeat

Fri, 31 Jul 2026
Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit - The Malone Telegram

Fri, 31 Jul 2026
CAPR INVESTOR ALERT: Class Action Lawsuit Filed on Behalf - GlobeNewswire

Fri, 31 Jul 2026
CAPRICOR THERAPEUTICS INC : B. RILEY CUTS TARGET PRICE TO $5 FROM $10 - Bitget

Thu, 30 Jul 2026
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	58 (M)
Shares Float	49 (M)
Held by Insiders	9.4 (%)
Held by Institutions	59.6 (%)
Shares Short	15,580 (K)
Shares Short P.Month	11,700 (K)

EPS	-2.32
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.82
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-31.3 %
Return on Equity (ttm)	-56.5 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	-1.61
Sales Per Share	0
EBITDA (p.s.)	-2.04
Qtrly Earnings Growth	0 %
Operating Cash Flow	-93 (M)
Levered Free Cash Flow	-70 (M)

PE Ratio	-1.66
PEG Ratio	0.3
Price to Book value	0.79
Price to Sales	0
Price to Cash Flow	-2.41

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.